Prediction of treatment response to rivastigmine in Alzheimer's dementia

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 2, 2004, Pages 292-294

  Adler, G ^a   Brassen, S ^a   Chwalek, K ^a   Dieter, B ^a   Teufel, M ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; FEMALE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MALE; MENTAL HEALTH; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; ORIENTATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; SCORING SYSTEM; SHORT TERM MEMORY; STATISTICAL SIGNIFICANCE; THETA RHYTHM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CARBAMATES; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THETA RHYTHM;

EID: 0842309197     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
2. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47.
3. Birks J, Grimley-Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000;4:CD001191.
4. Potkin SG, Anand R, Fleming K, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 2001;4:223-30.
5. Rombouts SA, Barkhof F, Van Meel CS, et al. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;74:665-71.
6. Maestu F, Arrazola J, Fernandez A, et al. Do cognitive patterns of brain magnetic activity correlate with hippocampal atrophy in Alzheimer's disease? J Neurol Neurosurg Psychiatry 2003;74:208-12.
7. Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 2001;43:273-6.
8. Riekkinen P, Buzsaki G, Riekkinen P, et al. The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 1991;78:89-96.
9. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000;356:2031-6.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Social Services task forces on Alzheimer's disease. Neurology 1984;34:939-44.
11. Folstein MF, Folstein SE, McHugh PR. "Mini mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Zaudig M, Mittelhammer J, Hiller W, et al. SIDAM - a structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other oetiology according to ICD-10 and DSM-III-R. Psychol Med 1991;21:225-36.
13. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md Med J 1965;14:61-5.
14. Lawton MP, Brodie EM. Assessment of older people, self maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86.
15. Reisberg B, Ferris S, de Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
16. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8.
17. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42.
18. Jelic V, Dierks T, Amberla K, et al. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neurosci Lett 1998;254:85-8.
19. Kogan EA, Korczyn AD, Virchovsky RG, et al. EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. J Neurol Transm 2001;108:1167-73.
20. Alhainen K, Riekkinen PJ. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand 1993;149(suppl):16-21.
21. Knott V, Mohr E, Mahoney C, et al. Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease. Methods Find Exp Clin Pharmacol 2000;22:115-22.
22. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-14.
23. Rockwood K, Graham JE, Fay S, et al. Goal setting an attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002;73:500-7.